ALK and neoplasm: Recently the early results of a phase I/II study with lorlatinib in heavily pretreated chemo and ALK/ROS1 TKIs showed an interesting response rate of 44% with a safe profile demonstrating the activity of this compound even in tumours considered highly refractory to ALK inhibition [86].